Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susanne Sprung

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Medizinische Genetik : Mitteilungsblatt Des Berufsverbandes Medizinische Genetik E.V|April 23, 2026
Christine Fauth, Susanne Sprung, Martina Messner BSc, et al.
Oncotarget|May 14, 2016
Clinical impact of L1CAM expression measured on the transcriptome level in ovarian cancerSamira Abdel Azim, Michaela Duggan-Peer, Susanne Sprung, et al.
Carcinogenesis|April 18, 2020
TNFα signalling predicts poor prognosis of patients with endometrial cancerVerena Wieser, Samira Abdel Azim, Susanne Sprung, et al.
Frontiers in Immunology|December 13, 2024
Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapyRaphael Gronauer, Leonie Madersbacher, Pablo Monfort-Lanzas, et al.
Journal of Surgical Oncology|December 3, 2019
Early response evaluation during preoperative chemotherapy for colorectal liver metastases: Combined size and morphology-based criteria predict pathological response and survival after resectionFlorian Primavesi, Nikolaus Fadinger, Simon Biggel, et al.
International Journal of Cancer|December 5, 2019
High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcomeDominik Wolf, Heidi Fiegl, Alain G Zeimet, et al.
International Journal of Molecular Sciences|April 13, 2023
Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with TemozolomideKonstantin R Brawanski, Susanne Sprung, Christian F Freyschlag, et al.
Oncotarget|May 1, 2018
<i>BRCA1/2</i> and <i>TP53</i> mutation status associates with <i>PD-1</i> and <i>PD-L1</i> expression in ovarian cancerVerena Wieser, Inge Gaugg, Martina Fleischer, et al.
British Journal of Cancer|August 17, 2018
BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancerIrina Tsibulak, Verena Wieser, Christine Degasper, et al.
Cells|April 3, 2021
KLF4, Slug and EMT in Head and Neck Squamous Cell CarcinomaJulia Ingruber, Dragana Savic, Teresa Bernadette Steinbichler, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Medizinische Genetik : Mitteilungsblatt Des Berufsverbandes Medizinische Genetik E.V|April 23, 2026
Christine Fauth, Susanne Sprung, Martina Messner BSc, et al.
Oncotarget|May 14, 2016
Clinical impact of L1CAM expression measured on the transcriptome level in ovarian cancerSamira Abdel Azim, Michaela Duggan-Peer, Susanne Sprung, et al.
Carcinogenesis|April 18, 2020
TNFα signalling predicts poor prognosis of patients with endometrial cancerVerena Wieser, Samira Abdel Azim, Susanne Sprung, et al.
Frontiers in Immunology|December 13, 2024
Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapyRaphael Gronauer, Leonie Madersbacher, Pablo Monfort-Lanzas, et al.
Journal of Surgical Oncology|December 3, 2019
Early response evaluation during preoperative chemotherapy for colorectal liver metastases: Combined size and morphology-based criteria predict pathological response and survival after resectionFlorian Primavesi, Nikolaus Fadinger, Simon Biggel, et al.
International Journal of Cancer|December 5, 2019
High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcomeDominik Wolf, Heidi Fiegl, Alain G Zeimet, et al.
International Journal of Molecular Sciences|April 13, 2023
Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with TemozolomideKonstantin R Brawanski, Susanne Sprung, Christian F Freyschlag, et al.
Oncotarget|May 1, 2018
<i>BRCA1/2</i> and <i>TP53</i> mutation status associates with <i>PD-1</i> and <i>PD-L1</i> expression in ovarian cancerVerena Wieser, Inge Gaugg, Martina Fleischer, et al.
British Journal of Cancer|August 17, 2018
BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancerIrina Tsibulak, Verena Wieser, Christine Degasper, et al.
Cells|April 3, 2021
KLF4, Slug and EMT in Head and Neck Squamous Cell CarcinomaJulia Ingruber, Dragana Savic, Teresa Bernadette Steinbichler, et al.
Pageof 4